153 related articles for article (PubMed ID: 38342036)
41. Human herpesvirus 8 DNA in HIV-negative Japanese patients with multicentric Castleman's disease and related diseases.
Tohda S; Murakami N; Nara N
Int J Mol Med; 2001 Nov; 8(5):549-51. PubMed ID: 11605026
[TBL] [Abstract][Full Text] [Related]
42. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
43. Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review.
Leroy S; Moshous D; Cassar O; Reguerre Y; Byun M; Pedergnana V; Canioni D; Gessain A; Oksenhendler E; Fieschi C; Mahlaoui N; Rivière JP; Herbigneaux RM; Muszlak M; Arnaud JP; Fischer A; Picard C; Blanche S; Plancoulaine S; Casanova JL
Pediatrics; 2012 Jan; 129(1):e199-203. PubMed ID: 22157133
[TBL] [Abstract][Full Text] [Related]
44. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Polizzotto MN; Uldrick TS; Wang V; Aleman K; Wyvill KM; Marshall V; Pittaluga S; O'Mahony D; Whitby D; Tosato G; Steinberg SM; Little RF; Yarchoan R
Blood; 2013 Dec; 122(26):4189-98. PubMed ID: 24174627
[TBL] [Abstract][Full Text] [Related]
45. HIV-associated Kaposi sarcoma and related diseases.
Gonçalves PH; Uldrick TS; Yarchoan R
AIDS; 2017 Sep; 31(14):1903-1916. PubMed ID: 28609402
[TBL] [Abstract][Full Text] [Related]
46. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis.
Viejo-Borbolla A; Schulz TF
AIDS Rev; 2003; 5(4):222-9. PubMed ID: 15012001
[TBL] [Abstract][Full Text] [Related]
47. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
[TBL] [Abstract][Full Text] [Related]
48. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8).
Sarid R; Klepfish A; Schattner A
Mayo Clin Proc; 2002 Sep; 77(9):941-9. PubMed ID: 12233927
[TBL] [Abstract][Full Text] [Related]
49. Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8: a new virus in human pathology.
Kemény L; Gyulai R; Kiss M; Nagy F; Dobozy A
J Am Acad Dermatol; 1997 Jul; 37(1):107-13. PubMed ID: 9216532
[TBL] [Abstract][Full Text] [Related]
50. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.
Carbone A; De Paoli P; Gloghini A; Vaccher E
Int J Cancer; 2015 Jul; 137(2):251-61. PubMed ID: 24771491
[TBL] [Abstract][Full Text] [Related]
51. Kaposi sarcoma herpesvirus-associated cancers and related diseases.
Goncalves PH; Ziegelbauer J; Uldrick TS; Yarchoan R
Curr Opin HIV AIDS; 2017 Jan; 12(1):47-56. PubMed ID: 27662501
[TBL] [Abstract][Full Text] [Related]
52. [HHV-8 Related immunological and hematological diseases].
Blaison F; Galtier J; Parrens M; Viallard JF; Boutboul D
Rev Med Interne; 2022 May; 43(5):301-311. PubMed ID: 34895767
[TBL] [Abstract][Full Text] [Related]
53. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.
Polizzotto MN; Uldrick TS; Hu D; Yarchoan R
Front Microbiol; 2012; 3():73. PubMed ID: 22403576
[TBL] [Abstract][Full Text] [Related]
54. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
[TBL] [Abstract][Full Text] [Related]
55. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
Kaplan LD
Hematology Am Soc Hematol Educ Program; 2013; 2013():103-8. PubMed ID: 24319170
[TBL] [Abstract][Full Text] [Related]
56. A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions.
Zhou T; Yuan CM; Lurain K; Rous C; Weaver L; Raffeld M; Stetler-Stevenson M; Uldrick TS; Filie AC; Pittaluga S; Jaffe ES; Marshall V; Moore K; Whitby D; Ramaswami R; Yarchoan R; Wang HW
Br J Haematol; 2023 Feb; 200(4):462-475. PubMed ID: 36264007
[TBL] [Abstract][Full Text] [Related]
57. Kaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesis.
Schulz TF; Cesarman E
Curr Opin Virol; 2015 Oct; 14():116-28. PubMed ID: 26431609
[TBL] [Abstract][Full Text] [Related]
58. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Yarchoan R
Curr Opin Oncol; 2012 Sep; 24(5):495-505. PubMed ID: 22729151
[TBL] [Abstract][Full Text] [Related]
59. Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies.
Patel R; Lurain K; Yarchoan R; Ramaswami R
Expert Rev Anti Infect Ther; 2023; 21(9):929-941. PubMed ID: 37578202
[TBL] [Abstract][Full Text] [Related]
60. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease.
Marcelin AG; Motol J; Guihot A; Caumes E; Viard JP; Dussaix E; Cadranel J; Frances C; Carcelain G; Calvez V; Dupin N
J Infect Dis; 2007 Oct; 196(8):1163-6. PubMed ID: 17955434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
